Literature DB >> 18807047

Management of low-risk prostate cancer.

Robert A Gardiner, Freddie C Hamdy.   

Abstract

Entities:  

Mesh:

Year:  2008        PMID: 18807047     DOI: 10.1007/s00345-008-0329-1

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  25 in total

1.  Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy.

Authors:  E David Crawford; Shandra S Wilson; Kathleen C Torkko; Daisaku Hirano; J Scott Stewart; Craig Brammell; R Storey Wilson; Nozomu Kawata; Holly Sullivan; M Scott Lucia; Priya N Werahera
Journal:  BJU Int       Date:  2005-11       Impact factor: 5.588

2.  Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.

Authors:  Richard Choo; Laurence Klotz; Cyril Danjoux; Gerard C Morton; Gerrit DeBoer; Ewa Szumacher; Neil Fleshner; Peter Bunting; George Hruby
Journal:  J Urol       Date:  2002-04       Impact factor: 7.450

3.  Prostate cancer and the Will Rogers phenomenon.

Authors:  Peter C Albertsen; James A Hanley; George H Barrows; David F Penson; Pam D H Kowalczyk; M Melinda Sanders; Judith Fine
Journal:  J Natl Cancer Inst       Date:  2005-09-07       Impact factor: 13.506

4.  Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer.

Authors:  Steven B Zeliadt; Arnold L Potosky; David F Penson; Ruth Etzioni
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-08-14       Impact factor: 7.038

Review 5.  Australian and New Zealand three-dimensional conformal radiation therapy consensus guidelines for prostate cancer.

Authors:  M Skala; M Berry; G Duchesne; K Gogna; K-H Tai; S Turner; A Kneebone; A Rolfo; A Haworth
Journal:  Australas Radiol       Date:  2004-12

Review 6.  The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review.

Authors:  Patricia Harnden; Michael D Shelley; Hayley Clements; Bernadette Coles; R Sandy Tyndale-Biscoe; Brian Naylor; Malcolm D Mason
Journal:  Cancer       Date:  2007-01-01       Impact factor: 6.860

7.  Quality of life after radical prostatectomy or watchful waiting.

Authors:  Gunnar Steineck; Fred Helgesen; Jan Adolfsson; Paul W Dickman; Jan-Erik Johansson; Bo Johan Norlén; Lars Holmberg
Journal:  N Engl J Med       Date:  2002-09-12       Impact factor: 91.245

8.  Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy.

Authors:  Hsiang-Hsuan M Yu; Danny Y Song; Ya-Yu Tsai; Travis Thompson; Deborah A Frassica; Theodore L DeWeese
Journal:  Urology       Date:  2007-07       Impact factor: 2.649

9.  TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.

Authors:  Sven Perner; Juan-Miguel Mosquera; Francesca Demichelis; Matthias D Hofer; Pamela L Paris; Jeff Simko; Colin Collins; Tarek A Bismar; Arul M Chinnaiyan; Angelo M De Marzo; Mark A Rubin
Journal:  Am J Surg Pathol       Date:  2007-06       Impact factor: 6.394

10.  Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer.

Authors:  G Attard; J Clark; L Ambroisine; G Fisher; G Kovacs; P Flohr; D Berney; C S Foster; A Fletcher; W L Gerald; H Moller; V Reuter; J S De Bono; P Scardino; J Cuzick; C S Cooper
Journal:  Oncogene       Date:  2007-07-16       Impact factor: 9.867

View more
  2 in total

1.  The impact of core biopsy fragmentation in prostate cancer.

Authors:  Leonardo Oliveira Reis; José Alberto Salvo Reinato; Daniel Carlos Silva; Wagner Eduardo Matheus; Fernandes Denardi; Ubirajara Ferreira
Journal:  Int Urol Nephrol       Date:  2010-03-11       Impact factor: 2.370

2.  Markers for detection of prostate cancer.

Authors:  Raymond A Clarke; Horst J Schirra; James W Catto; Martin F Lavin; Robert A Gardiner
Journal:  Cancers (Basel)       Date:  2010-06-04       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.